United Therapeutics Corporation (UTHR)

Rating: HOLD

HOLD (5-tier) · mature cash generator · conviction: medium

EPS basis for the forward P/E and all scenario multiples: consensus forward EPS (broker-adjusted, non-GAAP).

Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-07-21. Each chart below sits with the part of the thesis it evidences.

General research for a skeptical institutional reader. Not personalised investment advice; no position sizing or trade instructions. Figures as of the analysis date; verify before acting.

Investment Committee Summary

📎 Download the full model (Excel) — DCF line items, scenarios, sensitivity, assumptions, and extended fundamentals.

Rating Bridge

Rating = HOLD because:

• Probability-weighted scenario value implies -3% vs spot
• Monte Carlo median implies -12% vs spot
• DCF fair value implies -6% vs spot
• Bear case (Structural — Patent Cliff (LOE) / IRA Pricing Erosion) downside is -57% vs spot
• Net: reward/risk of 0.1× is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.

Company Overview & Business Model

United Therapeutics Corporation — HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC. United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.

How it makes money.

Edge. Wide moat — Wide competitive moat (inferred from a 42% operating margin and 20% ROE and the 'biopharma' business model). Durable pricing power supports a terminal multiple above the market.

Investment Thesis

[DRAFT — analyst to replace with a first-person thesis] At the current quote United Therapeutics Corporation is fairly valued vs the engine's triangulated fair value (-3%). The business — United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. — runs an operating margin near 42% on ~20% ROE. The engine's HOLD rests on the 'biopharma' driver set and the cluster's house view; the bull case is upside re-rating if the demand cycle inflects.

The dashboard below is the whole argument on one page: spot ($529) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

[DRAFT — steelman for review] The bear case is a demand downcycle that compresses volumes and the 42% margin simultaneously, with the multiple de-rating as cyclical earnings roll over — the structural scenario in the model. For a mid-cap with thinner coverage, a single guidance cut can re-rate the stock faster than a large-cap peer.

Key Debate

P/E Multiple explains 86% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q1): management +0.27 vs analyst floor +0.00 → delta +0.27 (n=23 mgmt / 7 Q&A; 27th pctile across the S&P book, z -0.7).

Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.

News (last 365d, 420 articles): avg ticker sentiment +0.17 (bullish 30% / bearish 1%)

Scenario Analysis

The tree runs from a structural 'Structural — Patent Cliff (LOE) / IRA Pricing Erosion' downside ($227) to a 'Bull — Blockbuster / Pipeline Re-Rate' bull case ($913); the probability-weighted blend (PWEV $516) is -3% versus spot.

Scenario rationale — what each probability buys (the driver path behind every target):

• Structural — Patent Cliff (LOE) / IRA Pricing Erosion (20%, $227). Structural impairment — patent cliff (LOE) / IRA pricing erosion: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 227.06; probability: 0.2.
• Pipeline Setback / Pricing Pressure (17%, $386). Cyclical downturn — drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory weakens for 1–2 years before normalising. Drivers — implied_target: 385.59; probability: 0.17.
• Base — Pipeline Offsets LOE (35%, $536). Mid-cycle — normalised drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory; disciplined capital allocation; steady returns. Drivers — implied_target: 535.54; probability: 0.35.
• Growth — Launch / Indication Expansion (20%, $723). Upside — pipeline launches + indication expansion lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 722.97; probability: 0.2.
• Bull — Blockbuster / Pipeline Re-Rate (8%, $913). Upside tail — sustained tight conditions or a structural re-rate on pipeline launches + indication expansion. Drivers — implied_target: 913.09; probability: 0.08.

Valuation Triangulation

Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the distribution, not a point

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $466 and 35% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (86% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 16x terminal FCF multiple → $496. This anchor is deliberately the heaviest (47%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median forward multiple (P/E 14.83x) implies —. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 0% so the market's mood does not drive the fair value.

Across all anchors the spread is 15% of the median — moderate (healthy method disagreement — read the blend with care).

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Health Pharma

This name sits in the Health Pharma as a biopharma. drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: UTHR (biopharma) · NBIX (biopharma) · JAZZ (biopharma) · EXEL (biopharma) · ELAN (biopharma) · BMRN (biopharma) · CYTK (biopharma) · ARWR (biopharma) · HALO (biopharma) · RGEN (biopharma)

Mapping note: name-level 'Structural — Patent Cliff (LOE) / IRA Pricing Erosion' (20%) + 'Pipeline Setback / Pricing Pressure' (17%) map to cluster Patent Cliff / IRA Pricing Erosion (37%); name-level 'Growth — Launch / Indication Expansion' (20%) + 'Bull — Blockbuster / Pipeline Re-Rate' (8%) map to cluster Upside — Launches / Pipeline Re-Rate (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.

On the cluster's key downside — Patent Cliff / IRA Pricing Erosion () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The health_pharma cycle is the shared macro driver. Driver — drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 6% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $5B + PV(terminal) $15B = EV $20B; + net cash $1.1B → equity $21B ÷ diluted shares 0.04B = $496/share (exit-multiple terminal).

• Gordon (perpetuity-growth) terminal at 2.5% → $519/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 22% vs WACC 8% → above WACC — the build is value-creative.

Peer set

Peer-median fwd P/E → —; EV/Rev → $441.

Weighted fair-value math

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Biopharma multiple (AI re-rating) (base 19x)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1% of revenue; cash conversion (OCF/NI) 117% — cash-backed.

Catalyst Calendar

• 2026-07-29 (~8d) — Quarterly earnings — est. EPS $6.83 (AV EARNINGS_CALENDAR)
• 2026-07-29 (~8d) — Quarterly earnings (AV EARNINGS_CALENDAR)

Forecast Track Record

• EPS surprise: beat 37.5% of the last 8 quarters; average surprise -2.1%.

Competitive Moat

Wide moat. Wide competitive moat (inferred from a 42% operating margin and 20% ROE and the 'biopharma' business model). Durable pricing power supports a terminal multiple above the market.

Scenario Macro & Key Risks

What the Market Is Pricing In

At the current price, the market pays 16.8× consensus forward EPS, vs the house DCF terminal 16.0×, and a peer median 14.83×. The house DCF sits 6% below spot, so the market is pricing in more than the house case — roughly 0.8pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily FCF-driven.

Peer Quality & Weighting

Quality-weighted forward P/E: 17.7× (simple median 14.83×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $272–$609, centre $407 (-23% vs spot); spot sits at the 76th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

Reward/risk compares triangulated upside against the probability-weighted bear target, not the extreme tail. Bull case (Bull — Blockbuster / Pipeline Re-Rate): $913.

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Revenue CAGR ±3pp (114.0); Terminal × ±15% (105.0); Op margin ±3pp (65.0); WACC ±1pp (39.0); Capex intensity ±15% (23.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Source Log

Citation coverage: 11/14 mandated claims sourced. Filing URLs are not available via the market-data provider; company statements are cited as 10-K/10-Q via Alpha Vantage.

Load-Bearing Assumptions

DCF: WACC 8%, terminal multiple 16×, FY+5 revenue $4B. Triangulation leans 47% on DCF, 33% on PWEV.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Organic revenue growth / order backlog < flat-to-negative for two consecutive quarters (2 consecutive prints → health_pharma). Sustained demand rollover breaks the base case toward the recession scenario.

Fact / Inference / Speculation

• FACT: Spot $529; 52-week range $272–$609; engine rating HOLD; house target $516 (-3%). (source: Alpha Vantage 2026-07-21, 21 July 2026)
• INFERENCE: Triangulated FV $497 (-6% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.

Recommendation: HOLD

Balanced: triangulated fair value $497 (-6% vs spot); the outcome hinges on P/E Multiple. The debate is P/E Multiple — fundamentally a multiple/regime call.

Options Overlay

A defined-risk way to express the HOLD equity view. Chain as of 2026-07-20 (last close) — indicative, not executable quotes.

Market signals — ATM IV 38.6% (elevated regime) · expected move ±8.7% (2026-08-21) · put/call OI 1.7 · ATM Δ 0.53 / Θ -0.411 / ν 0.624 · next earnings 2026-07-29. Direction: NEUTRAL (implied return -6.2% to triangulated fair value $496.61).

Covered Call (if held) (Income / neutral) — Short 570 C · 2026-08-21 · premium $11.4 · yield 2.15% · live chain

Converts a near-fair holding into income by agreeing to sell at a higher strike — worth weighing when upside looks limited near fair value and being called away is acceptable. Elevated implied volatility currently enriches the premium collected. Illustrative — no outcome is implied or guaranteed.

Put Spread (income) (Income / would-own) — Short 490 P / Long 450 P · 2026-08-21 · net $3.38 · net entry $486.62 · yield 0.7% · RoR 9% · max loss $36.62 · live chain

Gets paid to wait for a lower entry, with the tail capped: the sold put collects premium while the cheaper long wing below it caps the maximum loss at the spread width — a defined-risk alternative to a naked cash-secured put. Elevated implied volatility currently enriches the premium collected. Illustrative — no outcome is implied or guaranteed.

Protective Collar (if held) (Hedge) — Long 480 P / Short 580 C · 2027-01-15 · net $11.2 · floor -9% · cap +10% · live chain

For a holder who wants to stay invested but cap risk: the sold call funds most of the protective put, fencing the position into a band — a way to ride out a de-rating without selling. Elevated implied volatility currently enriches the premium collected. Illustrative — no outcome is implied or guaranteed.

Indicative options structures — a defined-risk expression of the equity view, model-and-market illustrated from the last-close chain. NOT personalised advice or an executable quote; premiums, IV and greeks move intraday. Options carry the risk of total loss of premium. Not a registered financial adviser.

Data Sources

• Prices, fundamentals, options chain, earnings — Alpha Vantage.
• Company filings (10-K / 10-Q) — SEC filings via EDGAR.

Disclosures & Limitations

This report is for informational and research purposes only. It is not personalised investment advice and does not consider any investor's objectives, financial situation, risk tolerance, tax position, or liquidity needs.

• No suitability assessment has been performed for any individual.
• Market data may be delayed or inaccurate; figures are as of the analysis date.
• Model outputs (fair values, targets, scenario probabilities) are estimates and may be wrong.
• Forecasts are uncertain; past performance is not indicative of future returns.
• The author or publisher may hold positions in securities mentioned.
• Users should verify information against primary sources (company filings) before acting.
• Investing involves risk of loss; there is no guarantee any target price is achieved.
• Ratings follow a defined research methodology (12-month expected-return thresholds), not individual circumstances.